• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Monash University

Headquarters: Clayton, Australia
Website: http://www.monash.edu.au
Year Founded: 1958
Status: Non-biopharma

Biopharma related deals can be found by searching the organization's name in the Deals Module.

BioCentury | Oct 23, 2024
Discovery & Translation

Science Spotlight: Novo’s glucose-sensing insulin, two bacterial immunotherapies, and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Apr 9, 2024
Emerging Company Profile

Karuna team, backers reunite for neuropsychiatry play Seaport’s launch

PureTech’s Zohar, Karuna’s Paul among team advancing prodrug candidates for anxiety and depression that avoid hepatic absorption
Read More
BioCentury | Jan 20, 2024
Discovery & Translation

Omics points to drivers of myeloid cancer, long COVID; plus ILC2 cell therapies and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Aug 23, 2023
Discovery & Translation

Resetting the iPS cell epigenome; plus microglia-targeted AAV and more

BioCentury’s roundup of translational innovations
Read More
BioCentury | Jan 31, 2023
Distillery Therapeutics

Inhibiting ADAM17 for pancreatitis

Read More
BioCentury | Jan 25, 2023
Emerging Company Profile

Fauna Bio: finding human drug targets using animal omics data

Bay Area biotech is taking a comparative genomics approach, starting with biobank data from the thirteen-lined ground squirrel
Read More
BioCentury | Jan 28, 2022
Emerging Company Profile

Septerna: Bringing next-generation drug discovery to GPCRs

Third Rock’s Septerna launches to bring new life to GPCRs with Robert Lefkowitz’s latest technology
Read More
BioCentury | Feb 27, 2021
Translation in Brief

A $53M UC Berkeley-UCSF-Genentech-Roche collaboration on brain diseases; plus Selecta, JDRF-Harvard Stem Cell Institute, Tissue Dynamics and more

BioCentury’s roundup of translational news
Read More
BioCentury | Sep 19, 2020
Translation in Brief

Gene therapies from Passage Bio, Locanabio; Lava’s antitumor bispecific, health disparities in Alzheimer’s and more

BioCentury’s roundup of translational news
Read More
BioCentury | Jun 27, 2020
Product Development

A mechanistic view of four compounds that disrupt interleukin pathways to treat severe COVID-19

The biological rationale behind the popular approach of using rheumatoid arthritis drugs to treat COVID-19
Read More
Items per page:
1 - 10 of 109